Enclomiphene Citrate Research: SERM Mechanism, Testosterone Studies & Hormonal Effects

For laboratory and research use only. Not for human consumption.

What Is Enclomiphene?

Clomiphene has been around since the 1960s. One of the oldest SERMs in the book. But here’s the thing most people don’t realize: it’s actually two drugs duct-taped together. The racemic mixture contains a trans-isomer (enclomiphene) that blocks estrogen receptors and a cis-isomer (zuclomiphene) that activates them. One foot on the gas, one on the brake. For decades, researchers just lived with that contradiction.

Enclomiphene is what you get when you strip the racemic mixture down to just the trans-isomer — the antiestrogenic half. Pure ER antagonism at the hypothalamus and pituitary. No estrogenic counterweight fighting against it. No 30-day zuclomiphene half-life slowly building up in the background and muddying your results.

For researchers studying the HPG axis, gonadotropin regulation, or estrogen receptor pharmacology, that’s not a minor upgrade. It’s a different compound entirely. Here’s what the data shows and why it matters.

Chemical Identity and Classification

Enclomiphene is the (E)-geometric isomer of clomiphene — trans configuration around the central double bond. Usually studied and sold as the citrate salt.

• Generic Names: Enclomiphene (USAN), enclomifene (INN)
• Molecular Formula (free base): C₂₆H₂₈ClNO
• Molecular Weight (free base): 405.96 g/mol
• Molecular Formula (citrate salt): C₃₂H₃₆ClNO₈
• Molecular Weight (citrate salt): 598.08 g/mol
• CAS Number (citrate): 7599-79-3
• UNII: J303A6U9Y6
• ChEMBL ID: CHEMBL1200667
• Classification: Nonsteroidal SERM, triphenylethylene derivative
• Stereochemistry: (E)-isomer — trans configuration

That (E) vs. (Z) geometry isn’t just a labeling detail. It determines which receptors the molecule activates vs. blocks. Different shape, different pharmacology. Completely.

From Clomiphene to Enclomiphene: The Development Story

To understand enclomiphene, you need to understand the problem it was designed to solve.

The Clomiphene Problem

Clomiphene citrate — Clomid, Serophene, whatever you want to call it — is roughly 62% enclomiphene and 38% zuclomiphene. First synthesized in the late 1950s. FDA-approved in 1967. Decades of use in reproductive endocrinology research. But here’s the issue: those two isomers do opposite things. Enclomiphene blocks estrogen receptors and pushes gonadotropin release up. Zuclomiphene activates estrogen receptors and pushes it down. You’re running both programs at once. Try designing a clean dose-response study around that.

Androxal: Isolating the Useful Half

Repros Therapeutics thought the answer was obvious — just use the trans-isomer by itself. They developed enclomiphene as Androxal® (later EnCyzix). The pitch: pure antiestrogenic HPG axis activation without zuclomiphene fighting against you the whole time.

The regulatory path didn’t go smoothly. FDA sent a Complete Response Letter in 2015 wanting more data. In January 2018, the EMA’s CHMP recommended against marketing authorization. As of today, enclomiphene has zero regulatory approvals anywhere. It’s still an investigational compound — which, for research purposes, doesn’t diminish its utility as a pharmacological tool at all.

Mechanism of Action: How Enclomiphene Activates the HPG Axis

The mechanism is elegant and well-understood. It’s textbook SERM pharmacology, but applied specifically to the hypothalamic-pituitary feedback loop.

Normal Feedback: What’s Happening Baseline

Estradiol circulates in blood. Hits ERα receptors in the hypothalamus. Hypothalamus dials back GnRH pulses. With less GnRH reaching the pituitary, LH and FSH secretion drops. Lower LH means lower gonadal stimulation. Lower testosterone production. That’s negative feedback — the system keeping itself in check.

What Enclomiphene Does to That Loop

It parks on estrogen receptors in the hypothalamus and pituitary. Sits there. Blocks estradiol from binding. Now the brain can’t “see” the estrogen that’s actually circulating. As far as the hypothalamic-pituitary unit is concerned, estrogen is low — even when it’s not.

Response? GnRH pulses speed up and get bigger. LH and FSH pour out of the pituitary. Gonads get hammered with stimulation. Testosterone production ramps.

And here’s the critical distinction from exogenous testosterone: the HPG axis stays on. Actually, it’s more active than usual. Spermatogenesis continues — even improves in some models. You’re not replacing the system. You’re tricking it into working harder. Completely different from injecting testosterone directly, which would shut the whole axis down.

Enclomiphene vs. Zuclomiphene: Night and Day

This comparison isn’t academic — it’s the entire reason enclomiphene exists as a separate compound.

Parameter	Enclomiphene (Trans/E)	Zuclomiphene (Cis/Z)
ER Activity	Antiestrogenic (blocks ERs)	Estrogenic (activates ERs)
HPG Axis Effect	Progonadotropic — increases LH/FSH	Antigonadotropic — suppresses LH/FSH
Half-Life	~10 hours	~30 days
Tissue Selectivity	ER antagonism in hypothalamus/pituitary	ER agonism in multiple tissues
Testosterone Effect (Male Models)	Increases	Decreases
Accumulation	Minimal — clears in hours	Massive — half-life is a month

Look at those half-lives. Ten hours vs. thirty days. That’s not a rounding error — it’s a 72-fold difference. Every time you dose racemic clomiphene, more zuclomiphene stacks up in the system because it barely clears. Week after week, the estrogenic counterweight grows heavier. That pharmacokinetic mismatch is a nightmare for research design.

With enclomiphene alone? Predictable steady-state. Clean washout in a day or two. You know what’s in the system and when it leaves. For anyone designing controlled endocrine studies, that difference is worth the price of admission by itself.

Research Findings

HPG Axis Activation

Enclomiphene drives LH and FSH up. Consistently. Across models. The gonadotropin bump matches what you’d predict from its ER antagonist mechanism — block estrogen feedback, gonadotropins rise. In male animal models, that translated to elevated endogenous testosterone without suppressing spermatogenesis. That last part is key. Exogenous testosterone shuts sperm production down. Enclomiphene does the opposite.

Testosterone Dynamics

Both total and free testosterone go up. What doesn’t go up disproportionately: DHT. Researchers interpret this to mean enclomiphene normalizes production through physiological pathways rather than brute-forcing supraphysiological levels. The axis self-regulates. Feedback loops stay operational. You get a testosterone increase that looks natural because the machinery producing it is natural.

Versus Exogenous Testosterone

The comparison is stark. Give exogenous testosterone and you suppress LH, suppress FSH, suppress endogenous production, and crush spermatogenesis. Give enclomiphene and the axis fires up — LH rises, FSH rises, endogenous production climbs, spermatogenesis stays intact or improves. Same endpoint (more testosterone). Completely different mechanistic route. Researchers studying HPG axis physiology need to understand that distinction because the downstream biology diverges enormously.

Metabolic Parameters

Secondary findings in some studies: changes in insulin sensitivity markers and lipid profiles associated with enclomiphene-driven testosterone shifts. Early data. Not well-characterized yet. But the relationship between ER modulation, gonadotropin dynamics, and metabolic endpoints is an open question that multiple labs are pursuing.

Enclomiphene vs. Racemic Clomiphene: Practical Research Considerations

Which one do you use? Depends on what you’re studying.

Pick enclomiphene if you want clean pharmacology. One mechanism. Predictable kinetics. No zuclomiphene accumulation muddying dose-response curves. Ideal for studying pure ER antagonism effects on gonadotropin output.

Pick racemic clomiphene if your study specifically needs to model the interplay between ER agonism and antagonism — because that mixed pharmacology is the reality of how the racemic drug behaves in vivo.

Loti Labs carries both: Enclomiphene 25mg/ml ($49.99) and Clomiphene 40mg/ml ($39.99).

Where Enclomiphene Fits Among SERMs

Enclomiphene is a triphenylethylene SERM — same chemical family as tamoxifen and toremifene. All three modulate estrogen receptors. All three have different tissue selectivity profiles and metabolic pathways.

• Tamoxifen generates active metabolites — 4-hydroxytamoxifen, endoxifen — each with their own receptor binding profiles. Mechanistic studies get complicated fast. More background in the Loti Labs tamoxifen review
• Enclomiphene has simpler metabolism, shorter half-life, and a more straightforward pharmacological profile. Better suited for acute and sub-chronic protocols where you want clear cause-and-effect
• Toremifene swaps in a different chlorine substitution pattern. Changes ER binding selectivity in tissue-dependent ways

If your research specifically targets HPG axis modulation through pituitary ER antagonism, enclomiphene’s profile makes it the most practical choice of the three. Related work on aromatase inhibition and estrogen management is covered in the anastrozole guide and estrogen inhibitor overview.

Safety Profile and Research Considerations

SERM territory, SERM considerations:

• ER modulation effects: Theoretical thromboembolic risk — standard concern for any compound that touches estrogen receptors. Factor it into protocol design
• No HPG suppression: Unlike exogenous androgens, enclomiphene doesn’t shut down the axis. No spermatogenesis loss. No testicular atrophy. That’s a fundamental difference from androgen replacement
• No androgenic side effects: Because it’s stimulating endogenous production (not adding exogenous hormone), you don’t see polycythemia or the other androgenic findings that accompany testosterone administration
• Visual disturbances: Racemic clomiphene has this in its adverse event profile. Whether it’s enclomiphene, zuclomiphene, or both causing it remains unclear

Enclomiphene is investigational. No FDA approval. No marketing authorization from any regulatory body. Interpret all data in the context of study design.

Regulatory Status

No approvals. Anywhere. The FDA sent a Complete Response Letter in 2015. The EMA CHMP recommended refusal in January 2018. Those decisions related to specific development program requirements — not safety signals that would affect legitimate research use. Racemic clomiphene citrate (the parent compound) does hold FDA approval. Enclomiphene isn’t a controlled substance and is legally available for laboratory research in the U.S.

Research Compound Availability

Loti Labs offers:

• Enclomiphene 25mg/ml — $49.99: Research-grade liquid, enclomiphene citrate
• Clomiphene 40mg/ml — $39.99: Racemic clomiphene citrate for comparative work

Third-party purity tested. Details on quality standards here.

Conclusion

Enclomiphene is clomiphene without the contradictions. One isomer. One mechanism. Predictable kinetics with a 10-hour half-life instead of zuclomiphene’s month-long accumulation. For HPG axis researchers, that clarity is the whole point.

It increases gonadotropins and testosterone through the body’s own feedback machinery — no axis suppression, no spermatogenesis shutdown, no exogenous hormone. Whether you’re studying ER antagonism, gonadotropin dynamics, or the mechanistic gap between SERM-mediated stimulation and direct androgen replacement, enclomiphene gives you a cleaner tool to work with than the racemic mixture ever could.

For laboratory and research use only. Not for human consumption.

References

1. Kaminetsky J, et al. Enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration versus alteration of the HPG axis. BMC Endocrine Disorders. 2013;13:45. doi:10.1186/1472-6823-13-45
2. Wiehle RD, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertility and Sterility. 2014;102(3):720-727. doi:10.1016/j.fertnstert.2014.06.004 (PMID: 25044080)
3. Kim ED, et al. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men. BJU International. 2016;117(4):677-685. doi:10.1111/bju.13313
4. Rodriguez KM, et al. Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opinion on Pharmacotherapy. 2016;17(11):1561-1567. doi:10.1080/14656566.2016.1204295 (PMID: 27337642)
5. Fontenot GK, et al. Zuclomiphene is estrogenic and antigonadotropic in male rats whereas enclomiphene is anti-estrogenic and progonadotropic. Biology of Reproduction. 2016;95(6):131. doi:10.1095/biolreprod.116.142935
6. European Medicines Agency. Refusal of the marketing authorisation for enclomifene (EnCyzix). EMA/30155/2018. January 2018.